[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Omeros Corp 201 ELLIOT AVENUE WEST SEATTLE WA 98119 USA

www.omeros.com Employees: 175 P: 206-676-5000 F: 206-676-5005

Sector:

Medical

Description:

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Key Statistics

Overview:

Market Capitalization, $K 846,788
Enterprise Value, $K 1,045,668
Shares Outstanding, K 72,375
Float, K 63,039
% Float 87.10%
Short Interest, K 15,790
Short Float 21.81%
Days to Cover 13.09
Short Volume Ratio 0.67
% of Insider Shareholders 12.90%
% of Institutional Shareholders 48.79%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -3,350 K
Last Quarter Sales, $ 9,890 K
Last Quarter Net Income, $ 56,060 K
EBIT, $ -105,240 K
EBITDA, $ -105,910 K

Growth:

1-Year Return 260.54%
3-Year Return 107.09%
5-Year Return -21.20%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 214.13%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.24 on 05/13/26
Next Earnings Date 08/13/26
Earnings Per Share ttm 2.18
EPS Growth vs. Prev Qtr -107.64%
EPS Growth vs. Prev Year 63.08%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

OMER Ratios

Ratio
Price/Earnings ttm 5.62
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -102.16%
Return-on-Assets % 64.87%
Profit Margin % 0.00%
Debt/Equity -2.16
Price/Sales 86.54
Price/Cash Flow 6.55
Price/Book N/A
Book Value/Share -0.88
Interest Coverage -3.92
60-Month Beta 2.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.